Funding the Low-Dose Lithium Research Study

Help Fund the Groundbreaking Lithium Inflammation Psychiatry study with Dr. Sudhir Gadh at Karolinska Institute.

Support the Lithium Inflammation Psychiatry (LIP) Study at Karolinska Institute

Meet the Research Team

Public & Mental Health Implications of Nutritional Low-Dose Lithium

Support the latest evidence-based research at the world-renowned Karolinska Institute on the transformative potential of nutritional low-dose lithium for mental health. This groundbreaking study, led by Dr. Sudhir Gadh, explores how low-dose lithium can improve brain health, regulate inflammation, and offer innovative, cost-effective solutions for mental well-being. Join us as we advance precision psychiatry, unlock new biomarkers, and pave the way for safer, more accessible mental health treatments worldwide. Support the Lithium Inflammation Psychiatry (LIP) study and be part of the future of mental health care.

Funding Opportunity at the World-Renowned Karolinska Institute on the Transformative Potential of Nutritional Low-Dose Lithium for Mental Health

We are actively seeking funding to support Dr. Sudhir Gadh’s groundbreaking, evidence-based research on nutritional low-dose lithium at the prestigious Karolinska Institute. This pioneering study aims to unlock a new understanding of how nutritional lithium can impact brain health, mental well-being, and the regulation of inflammation—offering hope for innovative, accessible mental health treatments. Your contribution will directly fuel this critical research and help drive real progress in the field.

Explore How Cutting-Edge Research into Biological Biomarkers is Transforming Psychiatry from Traditional Symptom-Based Diagnoses to Precision Medicine

Transform a life. Your support today can mean that one more individual who has severe mental illness receives the precise, effective care they deserve—restoring hope, health, and family bonds. Join us in furthering the Lithium Inflammation Psychiatry (LIP) study at the world-renowned Karolinska Institute in Solna, Sweden. This pioneering research is the first of its kind to explore how cutting-edge research into biological biomarkers is transforming psychiatry from traditional symptom-based diagnoses to precision medicine, offering more accurate, personalized treatment and improved patient outcomes. Think of it as upgrading from black-and-white television to ultra-high-definition 4K: for decades, psychiatry relied on general symptoms, but now we can see the fine details in each person’s unique brain biology. The LIP study continues to investigate how nutritional and low-dose lithium interventions may improve brain health, boost resilience, and regulate inflammation, possibly reshaping the care for mental health and inflammation-related conditions.

Help Create New, Cost-Effective, Evidence-Based Mental Health Treatments

Your generous donation will fuel innovative discoveries and help create new, cost-effective, evidence-based treatments for individuals in urgent need. Together, we can pave the way for safer, more accessible mental health solutions. Your contribution will directly fund the first 50 biomarker assays, which are essential to advancing our research. Please consider donating today and becoming an agent of optimism and recovery.

Public & Mental Health Implications of Nutritional Low-Dose Lithium

The public health consequences of this research are significant. Personality disorders such as Borderline personality disorder (BPD) impose high societal costs due to chronic disability, frequent hospitalizations or crisis interventions, and extensive medication use that often results in side effects requiring further care. In fact, the annual direct and indirect costs of treating a person with BPD can reach as high as $50,000 per year, stressing the major economic strain on families and medical systems alike. Consider Anna, a young woman who lives with BPD. Over the course of a year, Anna’s life is formed by repeated emergency room visits, several long inpatient stays, and a daily regimen of four different psychiatric medications. Each new medication brings side effects that require their own medical attention—weight gain, tremors, and headaches—affecting her ability to hold a steady job or maintain close relationships. Anna’s family regularly rearranges work schedules and finances to provide support, struggling to keep up with out-of-pocket medical expenses and the psychological burden of constant uncertainty.

Effective pharmaceutical treatments for this population remain limited. There is a critical need for treatments that are widely accessible, low-risk, and cost-effective. Early intervention with a targeted, low-risk treatment aims to reduce illness severity and subsequent healthcare costs for these patients. Low-dose lithium represents a nearly cost-free intervention. Lithium carbonate is an inexpensive generic medication, and at low doses, intensive laboratory monitoring is less necessary, enhancing workability in low-resource settings. If effective, low-dose lithium could significantly lower the reliance on multiple costly medications such as antipsychotics, antidepressants, and sedatives, which patients often use in the absence of a clear benefit. The difference is immediate and practical: Five pills, three refills, weekly labs become one capsule, one monthly check-in. This sharp contrast turns overwhelming complexity into elegant simplicity, making the value tangible for funders and patients alike. Simplifying treatment regimens in this way would reduce pharmacy expenses, improve medication adherence, and decrease cumulative side effects. Each additional psychotropic medication increases risks such as metabolic syndrome, sedation, and cognitive impairment, thereby exacerbating functional decline. In contrast, lithium’s side effect profile at low doses is minimal. Consequently, patients are more likely to maintain wellness and functionality, resulting in fewer emergency room visits and inpatient admissions.

Mental health disorders are among the leading causes of disability in the world, yet unlike heart disease or cancer, we lack objective biological markers that track illness severity or recovery. This absence has slowed progress, making treatment less precise and outcomes more unpredictable. Imagine if we could measure and track mental illness with the same clarity as we do cholesterol or blood sugar. With the right biomarkers, our ability to accurately diagnose, monitor progress, and customize treatments may revolutionize outcomes and bring new optimism to millions of people.

About Dr. Gadh

Dr. Sudhir Gadh is a psychiatrist, US Navy Commander, and researcher affiliated with the Karolinska Institute, one of the world's leading medical research centers. Drawing on his military leadership, Dr. Gadh brings a track record of disciplined adherence to protocol and ethical stewardship to every project he leads, reassuring funders that their investments are managed with the utmost rigor. He has spent years leading high-outcome clinical programs and studying the biology of mental illness. He is also the founder of Third Element Water.

What the Lithium Research Will Do:

Create the ‘inflammation dashboard’: We will build an easy-to-understand visual guide that shows changes in key inflammation and signaling biomarkers before and after the intervention. This will give clinicians a clear biological map to monitor patient progress over time.
Test whether nutritional low-dose lithium shifts these biomarkers (shows if a simple, affordable intervention triggers meaningful brain health changes).
Correlate those changes with clinical outcomes (connecting lab results to real-world patient improvements that funders care about).
Publish and share the data openly to accelerate the field (multiply the impact of your donation by promoting research everywhere).

This is not drug-level lithium or psychiatric dosing; it’s a safe, nutritional level similar to what people historically consumed in certain mineral springs. Think of it as comparable to the trace amount of fluoride added to the tap water: a tiny, carefully controlled dose that supports welfare without risk. This everyday analogy helps illustrate that our approach prioritizes both safety and effectiveness.

Why this Matters

Right now, the field of mental health is stuck treating symptoms instead of mechanisms. So why, despite decades of research, do we still rely on guesswork rather than biology? Your support will make it possible to:

Predict which individuals will respond best to specific treatments, tailoring care to individual needs.
Track recovery with clear, objective biological markers to help patients and families see real progress.
Reveal why conditions like depression, trauma, addiction, or cognitive decline differ so much between people—transforming care from trial-and-error to true precision medicine.

What We Need: Your Donations Will Help Fund

Lab assays for inflammatory and neurobiological markers.
Participant monitoring and clinical assessments.
Data collection, analysis, and publication.
Compliance, ethics oversight, and research infrastructure.

Why Lithium?

Lithium impacts key cellular pathways, including GSK-3 signaling, the master aging enzyme (Williams et al., 2019).
Trace lithium exposure correlates with lower suicide rates, dementia, and improved longevity in population studies (Williams et al., 2020)
Lithium modifies inflammation, which is implicated in depression, cognition, and PTS (Lee & Kim, 2022)

(Note: All claims are based on peer-reviewed publications, and full references are available on request.) Your help can be the first to thoroughly link these biomarkers with clinically observable results and low-dose lithium in a structured study. This is a unique opportunity to create a lasting legacy and catalyze a revolutionary change in mental health research.

All contributions, no matter how small, move this cause forward. For example, even a gift of $50 will allow us to analyze one additional blood sample, bringing us closer to breakthroughs in precision mental health care. Your support at any level makes a direct and quantifiable difference.

Why it's Urgent

Mental illness is not abstract; it affects real families, productivity, safety, and quality of life. Recent trends, based on data from the Substance Abuse and Mental Health Services Administration (SAMHSA), show that an estimated 1.7 million adults and 700,000 adolescents (aged 12-17) attempted suicide in the US alone, and tens of thousands will tragically lose their lives. Urgent action is now needed to change this trajectory. This study aims to transform mental health care from guesswork to biology.

Return on Investment (ROI) for Funder(s)

We acknowledge that funding bodies and stakeholders seek research that offers concrete benefits to patients and society. This study delivers high ROI in multiple key areas:

Paradigm-Changing Knowledge: Every $1 invested in this research could yield up to $12 in healthcare savings by reducing hospitalizations, polypharmacy, and crisis interventions for mental health patients. This high-impact ratio offers a clear and compelling ROI for funders. The investment could also present further evidence on whether inflammation is a viable therapeutic target in psychiatry. Positive results could stimulate a whole new line of treatment development, broadening the impact of this single trial across the field. Funding this work positions the sponsor at the forefront of a potential revolution in mental health treatment.
Improved Patient Outcomes: By investigating lithium as a potential treatment option, funders help improve the quality of life for a traditionally hard-to-treat population. Better emotional stability and reduced self-harm in even a subset of personality disorder patients will ripple out to healthier families, more stable workplaces, and less strain on mental health services. Each patient rescued from a cycle of crises and disability gains years of productive life.
Cost Effectiveness: Compared to the status quo (polypharmacy and long-term psychotherapy or hospital-based interventions), a simple low-dose lithium regimen is highly cost-effective. Lithium costs pennies per dose, and any reduction in hospitalizations or multi-drug use results in substantial savings for medical systems. Consider Maria, a hypothetical patient living with a personality disorder. Under traditional care, Maria required frequent hospital admissions, multiple psychiatric medications, and ongoing intensive therapy, bringing her total care costs to $17,442 per year. After converting to a low-dose lithium regimen as part of early intervention, she stabilized enough to need only periodic outpatient visits and a single affordable medication, reducing her annual care expenses to just $2,325 per year. This simple change freed up over $15,116 for her family and the healthcare system, while improving her quality of life. Even a modest effect size in a sizable patient population could save millions in healthcare expenditures by reducing ER visits, inpatient days, and concomitant medication use. From a payer perspective, this is an attractive potential return.
Scalability and Public Health Reach: If our trial is successful, the treatment regimen could be more widely studied and implemented, given lithium's wide availability and familiarity. The knowledge acquired could be translated into updated clinical guidelines following replication in larger studies, encouraging clinicians to measure inflammation (via simple blood tests) and to consider low-dose lithium in appropriate patients. Thus, the funder's support would have a worldwide impact, improving mental health outcomes broadly and aligning with public health priorities to reduce suicide and chronic mental illness burden.

Empower the Future of Mental Health: Fund Dr. Sudhir Gadh's Pioneering Research

We invite foundations, grant-makers, and philanthropic leaders to help drive the next breakthrough in mental healthcare by supporting Dr. Sudhir Gadh’s innovative study on nutritional interventions and low-dose lithium at the Karolinska Institute. Your grant, donation, or partnership will directly accelerate world-class research seeking safer, more accessible, and cost-effective treatments for those living with complex mental health conditions.